Oral administration of Alequel, a mixture of autologous colon-extracted proteins for the treatment of Crohn's disease

Therapeutic Advances in Gastroenterology

Volumn 3, Issue 1, 2010, Pages 23-30

  Israeli, Eran ^a   Ilan, Yaron ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Crohn's disease; Oral tolerance

Indexed keywords

ALEQUEL; ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; COLITIS; CROHN DISEASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOID TISSUE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

EID: 77953437060     PISSN: 1756283X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756283X09351733     Document Type: Review

References (78)

1. Bagchi, D., Misner, B., Bagchi, M., Kothari, S.C., Downs, B.W., Fafard, R.D. et al. (2002) Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: a mechanistic exploration. Int J Clin Pharmacol Res 22: 101-110.
2. Barker, J.M., McFann, K.K. and Orban, T. ( 2007) Effect of oral insulin on insulin autoantibody levels in the diabetes prevention trial type 1 oral insulin study. Diabetologia 50: 1603-1606.
3. Baumgart, D.C. and Carding, S.R. ( 2007) Inflammatory bowel disease: cause and immunobiology. Lancet 369: 1627-1640.
4. Baumgart, D.C. and Sandborn, W.J. ( 2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369: 1641-1657.
5. Bendelac, A., Savage, P.B. and Teyton, L. ( 2007) The biology of NKT cells. Ann Rev Immunol 25: 297-336.
6. Bergerot, I., Ploix, C., Petersen, J., Moulin, V., Rask, C., Fabien, N. et al. (1997) A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci U S A 94: 4610-4614.
7. Chin, R., Wang, J. and Fu, Y.X. ( 2003) Lymphoid microenvironment in the gut for immunoglobulin A and inflammation. Immunol Rev 195: 190-201.
8. Corthesy, B. ( 2007) Roundtrip ticket for secretory IGA: role in mucosal homeostasis ? J Immunol 178: 27-32.
9. Dahan, S., Roth-Walter, F., Arnaboldi, P., Agarwal, S. and Mayer, L. ( 2007) Epithelia: lymphocyte interactions in the gut. Immunol Rev 215: 243-253.
10. Dasgupta, A., Kesari, K.V., Ramaswamy, K.K., Amenta, P.S. and Das, K.M. ( 2001a) Oral administration of unmodified colonic but not small intestinal antigens protects rats from hapten-induced colitis. Clin Exp Immunol 125: 41-47.
11. Dasgupta, A., Ramaswamy, K., Giraldo, J., Taniguchi, M., Amenta, P.S. and Das, K.M. ( 2001b) Colon epithelial cellular protein induces oral tolerance in the experimental model of colitis by trinitrobenzene sulfonic acid. J Lab Clin Med 138: 257-269.
12. Drachman, D.B., Okumura, S., Adams, R.N. and Mcintosh, K.R. ( 1996) Oral tolerance in myasthenia gravis. Ann N Y Acad Sci 778: 258-272.
13. Egan, L.J. and Sandborn, W.J. ( 2004) Advances in the treatment of Crohn's disease. Gastroenterology 126: 1574-1581.
14. El Haj, M., Ya'acov, A.B., Lalazar, G. and Ilan, Y. ( 2007) Potential role of NKT regulatory cell ligands for the treatment of immune mediated colitis. World J Gastroenterol 13: 5799-5804.
15. Elson, C.O. ( 2002) Genes, microbes, and T cells- new therapeutic targets in Crohn's disease. N Engl J Med 346: 614-616.
16. Faria, A.M. and Weiner, H.L. ( 2005) Oral tolerance. Immunol Rev 206: 232-259.
17. Faria, A.M. and Weiner, H.L. ( 2006a) Oral tolerance and TGD-beta-producing cells. Inflamm Allergy Drug Targets 5: 179-190.
18. Faria, A.M. and Weiner, H.L. ( 2006b) Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol 13: 143-157.
19. Godfrey, D.I. and Kronenberg, M. ( 2004) Going both ways: immune regulation via CD1D-dependent NKT cells. J Clin Invest 114: 1379-1388.
20. Gotsman, I., Shlomai, A., Alper, R., Rabbani, E., Engelhardt, D. and Ilan, Y. ( 2001) Amelioration of immune-mediated experimental colitis: tolerance induction in the presence of preexisting immunity and surrogate antigen bystander effect. J Pharmacol Exp Ther 297: 926-932.
21. Himmel, M.E., Hardenberg, G., Piccirillo, C.A., Steiner, T.S. and Levings, M.K. ( 2008) The role of T-regulatory cells and toll-like receptors in the pathogenesis of human inflammatory bowel disease. Immunology 125: 145-153.
22. Ilan, Y. ( 2002) Immune downregulation leads to upregulation of an antiviral response: a lesson from the hepatitis B virus. Microbes Infect 4: 1317-1326.
23. Ilan, Y. (2009) Oral tolerance: can we make it work? Hum Immunol 70: 768-776.
24. Ilan, Y., Weksler-Zangen, S., Ben-Horin, S., Diment, J., Sauter, B., Rabbani, E. et al. (2000) Treatment of experimental colitis by oral tolerance induction: a central role for suppressor lymphocytes. Am J Gastroenterol 95: 966-973.
25. Ishikawa, H., Ochi, H., Chen, M.L., Frenkel, D., Maron, R. and Weiner, H.L. ( 2007) Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes 56: 2103-2109.
26. Israeli, E., Goldin, E., Shibolet, O., Klein, A., Hemed, N., Engelhardt, D. et al. (2005) Oral immune regulation using colitis extracted proteins for treatment of Crohn's disease: results of a phase I clinical trial. World J Gastroenterol 11: 3105-3111.
27. Javed, N.H., Gienapp, I.E., Cox, K.L. and Whitacre, C.C. ( 1995) Exquisite peptide specificity of oral tolerance in experimental autoimmune encephalomyelitis. J Immunol 155: 1599-1605.
28. Johansson-Lindbom, B. and Agace, W.W. ( 2007) Generation of gut-homing T cells and their localization to the small intestinal mucosa. Immunol Rev 215: 226-242.
29. Kelsall, B.L. and Leon, F. ( 2005) Involvement of intestinal dendritic cells in oral tolerance, immunity to pathogens, and inflammatory bowel disease. Immunol Rev 206: 132-148.
30. Klement, E., Lysy, J., Hoshen, M., Avitan, M., Goldin, E. and Israeli, E. ( 2008) Childhood hygiene is associated with the risk for inflammatory bowel disease: a population-based study. Am J Gastroenterol 103: 1775-1782.
31. Kolker, O., Klein, A., Alper, R., Menachem, Y., Shibolet, O., Rabbani, E. et al. (2003) Early expression of interferon gamma following oral antigen administration is associated with peripheral tolerance induction. Microbes Infect 5: 807-813.
32. Lee, S., Scherberg, N. and Degroot, L.J. ( 1998) Induction of oral tolerance in human autoimmune thyroid disease. Thyroid 8: 229-234.
33. Lehmann, P.V., Forsthuber, T., Miller, A. and Sercarz, E.E. ( 1992) Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358: 155-157.
34. Makala, L.H., Suzuki, N. and Nagasawa, H. ( 2002) Peyer's patches: organized lymphoid structures for the induction of mucosal immune responses in the intestine. Pathobiology 70: 55-68.
35. Marchesi, J. and Shanahan, F. ( 2007) The normal intestinal microbiota. Curr Opin Infect Dis 20: 508-513.
36. Margalit, M., Israeli, E., Shibolet, O., Zigmond, E., Klein, A., Hemed, N. et al. (2006) A double-blind clinical trial for treatment of Crohn's disease by oral administration of alequel, a mixture of autologous colon-extracted proteins: a patient-tailored approach. Am J Gastroenterol 101: 561-568.
37. Margalit, M., Shibolet, O., Klein, A., Elinav, E., Alper, R., Thalenfeld, B. et al. (2005) Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKT lymphocytes. Int J Cancer 115: 443-449.
38. Maron, R., Guerau-De-Arellano, M., Zhang, X. and Weiner, H.L. ( 2001) Oral administration of insulin to neonates suppresses spontaneous and cyclophosphamide induced diabetes in the NOD mouse. J Autoimmun 16: 21-28.
39. Miller, A., Zhang, Z.J., Sobel, R.A., Al-Sabbagh, A. and Weiner, H.L. ( 1993) Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. VI. Suppression of adoptively transferred disease and differential effects of
40. oral vs. intravenous tolerization. J Neuroimmunol 46: 73-82.
41. Miller, H., Zhang, J., Kuolee, R., Patel, G.B. and Chen, W. ( 2007) Intestinal M cells: the fallible sentinels? World J Gastroenterol 13: 1477-1486.
42. Mizrahi, M. and Ilan, Y. (2009) The gut mucosa as a site for induction of regulatory T-cells. Curr Pharm Des 15: 1191-1202.
43. Mowat, A.M. ( 2005) Dendritic cells and immune responses to orally administered antigens. Vaccine 23: 1797-1799.
44. Neurath, M.F., Fuss, I., Kelsall, B.L., Presky, D.H., Waegell, W. and Strober, W. ( 1996) Experimental Granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med 183: 2605-2616.
45. Niess, J.H. and Reinecker, H.C. ( 2006) Dendritic cells: the commanders-in-chief of mucosal immune defenses. Curr Opin Gastroenterol 22: 354-360.
46. Nussenblatt, R.B., Whitcup, S.M., de Smet, M.D., Caspi, R.R., Kozhich, A.T., Weiner, H.L. et al. (1996) Intraocular inflammatory disease (uveitis) and the use of oral tolerance: a status report. Ann N Y Acad Sci 778: 325-337.
47. Ochi, H., Abraham, M., Ishikawa, H., Frenkel, D., Yang, K., Basso, A.S. et al. (2006) Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- Lap+ T cells. Nat Med 12: 627-635.
48. Okamoto, K., Fukatsu, K., Ueno, C., Shinto, E., Hashiguchi, Y., Nagayoshi, H. et al. (2005) T lymphocyte numbers in human gut associated lymphoid tissue are reduced without enteral nutrition. JPEN J Parenter Enteral Nutr 29: 56-58.
49. Pozzilli, P., Pitocco, D., Visalli, N., Cavallo, M.G., Buzzetti, R., Crino, A. et al. (2000) No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the Imdiab VII). Imdiab group, Diabetologia 43: 1000-1004.
50. Rook, G.A. and Brunet, L.R. ( 2005) Microbes, immunoregulation, and the gut. Gut 54: 317-320.
51. Safadi, R., Israeli, E., Papo, O., Shibolet, O., Melhem, A., Bloch, A. et al. (2003) Treatment of chronic hepatitis B virus infection via oral immune regulation toward hepatitis B virus proteins. Am J Gastroenterol 98: 2505-2515.
52. Sands, B.E. ( 2000) Therapy of inflammatory bowel disease. Gastroenterology 118: S68-S82
53. Shibolet, O., Alper, R., Avraham, Y., Berry, E.M. and Ilan, Y. ( 2002) Immunomodulation of experimental colitis via caloric restriction: role of NK1.1+ T cells. Clin Immunol 105: 48-56.
54. Shibolet, O., Alper, R., Zlotogarov, L., Thalenfeld, B., Engelhardt, D., Rabbani, E. et al. (2003) NKT and CD 8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells. Int J Cancer 106: 236-243.
55. Shibolet, O., Alper, R., Zlotogarov, L., Thalenfeld, B., Engelhardt, D., Rabbani, E. et al. (2004 a) Suppression of hepatocellular carcinoma growth via oral immune regulation towards tumor-associated antigens is associated with increased NKT and CD8+ lymphocytes. Oncology 66: 323-330.
56. Shibolet, O., Kalish, Y., Klein, A., Alper, R., Zolotarov, L., Thalenfeld, B. et al. (2004 b) Adoptive transfer of ex vivo immune-programmed NKT lymphocytes alleviates immune-mediated colitis. J Leukoc Biol 75: 76-86.
57. Shlomai, A., Trop, S., Gotsman, I., Jurim, O., Diment, J., Alper, R. et al. (2001) Immunomodulation of experimental colitis: the role of NK1.1 liver lymphocytes and surrogate antigens - bystander effect. J Pathol 195: 498-507.
58. Singh, U.P., Singh, S., Singh, R., Cong, Y., Taub, D.D. and Lillard Jr, J.W. ( 2008) CXCl10-producing mucosal CD4+ T cells, NK cells, and NKT cells are associated with chronic colitis in Il-10(-/-) mice, which can be abrogated by anti-CXCL10 antibody inhibition. J Interferon Cytokine Res 28: 31-43.
59. Stanford, M., Whittall, T., Bergmeier, L.A., Lindblad, M., Lundin, S., Shinnick, T. et al. (2004) Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease. Clin Exp Immunol 137: 201-208.
60. Thompson-Chagoyan, O.C., Maldonado, J. and Gil, A. ( 2007) Colonization and impact of disease and other factors on intestinal microbiota. Dig Dis Sci 52: 2069-2077.
61. Thurau, S.R., Chan, C.C., Nussenblatt, R.B. and Caspi, R.R. ( 1997) Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): induction of protective tolerance in primed animals. Clin Exp Immunol 109: 370-376.
62. Thurau, S.R., Diedrichs-Mohring, M., Fricke, H., Burchardi, C. and Wildner, G. ( 1999) Oral tolerance with an HLA-peptide mimicking retinal autoantigen as a treatment of autoimmune uveitis. Immunol Lett 68: 205-212.
63. Tisch, R., Yang, X.D., Singer, S.M., Liblau, R.S., Fugger, L. and Mcdevitt, H.O. ( 1993) Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 366: 72-75.
64. Trentham, D.E. ( 1998) Oral tolerization as a treatment of rheumatoid arthritis. Rheum Dis Clin North Am 24: 525-536.
65. Trentham, D.E., Dynesius-Trentham, R.A., Orav, E.J., Combitchi, D., Lorenzo, C., Sewell, K.L. et al. (1993) Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261: 1727-1730.
66. Trop, S. and Ilan, Y. ( 2002) NK 1.1+ T cell: a two-faced lymphocyte in immune modulation of the IL-4/IFN-gamma paradigm. J Clin Immunol 22: 270-280.
67. Trop, S., Samsonov, D., Gotsman, I., Alper, R., Diment, J. and Ilan, Y. ( 1999) Liver-associated lymphocytes expressing NK1.1 are essential for oral immune tolerance induction in a murine model. Hepatology 29: 746-755.
68. van Dieren, J.M., van der Woude, C.J., Kuipers, E.J., Escher, J.C., Samsom, J.N., Blumberg, R.S. et al. (2007) Roles of CD1D-restricted NKT cells in the intestine. Inflamm Bowel Dis 13: 1146-1152.
69. Weiner, H.L. ( 1997) Oral tolerance for the treatment of autoimmune diseases. Ann Rev Med 48: 341-351.
70. Weiner, H.L. ( 2004) Current issues in the treatment of human diseases by mucosal tolerance. Ann N Y Acad Sci 1029: 211-224.
71. Weiner, H.L. and Komagata, Y. ( 1998) Oral tolerance and the treatment of rheumatoid arthritis. Springer Semin Immunopathol 20: 289-308.
72. Weiner, H.L., Mackin, G.A., Matsui, M., Orav, E.J., Khoury, S.J., Dawson, D.M. et al. (1993) Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259: 1321-1324.
73. Wu, H., Center, E., Tsokos, G. and Weiner, H. (2009) Suppression of murine SLE by oral anti-CD3: inducible CD4+CD25-Lap+ regulatory T cells control the expansion of IL-17+ follicular helper T cells. Lupus 18: 586-596.
74. Wu, H.Y. and Weiner, H.L. ( 2003) Oral tolerance. Immunol Res 28: 265-284.
75. Zhang, J., Markovic-Plese, S., Lacet, B., Raus, J., Weiner, H.L. and Hafler, D.A. ( 1994) Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 179: 973-984.
76. Zhang, J. and Raus, J. ( 1994) Myelin basic protein-reactive T cells in multiple sclerosis: pathologic relevance and therapeutic targeting. Cytotechnology 16: 181-187.
77. Zhang, X., Izikson, L., Liu, L. and Weiner, H.L. ( 2001) Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration. J Immunol 167: 4245-4253.
78. Zigmond, E., Preston, S., Pappo, O., Lalazar, G., Margalit, M., Shalev, Z. et al. (2007) Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphocyte plasticity in murine models of immune-mediated disorders. Gut 56: 82-89.